Basic Information
PERTAGEN® SUSPENSION FOR INJECTION 0.5 ML/DOSE
INJECTION, SUSPENSION
Regulatory Information
SIN16283P
July 23, 2021
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ07AJ02
Company Information
Active Ingredients
Strength: 5 ug/0.5 ml
Strength: 5 ug/0.5 ml
Detailed Information
Contraindications
**CONTRAINDICATION** **Pertagen®** should not be administered to individuals having shown signs of hypersensitivity or life-threatening reaction following administration of pertussis vaccines or to any components of the vaccine. Hypersensitivity to diphtheria and tetanus vaccines are not contraindication to the use of **Pertagen®**. **Pertagen®** should not be administered to individuals having experienced any encephalopathy with unknown aetiology such as coma, prolonged seizures, or decreased level of consciousness within 7 days following previous vaccination with any whooping cough vaccine. **Pertagen®** should not be administered to individuals with progressive or unstable neurological disorders, uncontrolled epilepsy or progressive encephalopathy.
Indication Information
**INDICATION** **Pertagen®** is indicated for active booster immunization against pertussis in individuals from the age of 11 years onwards. **Pertagen®** may be considered as an alternative to combined tetanus, diphtheria and acellular pertussis vaccines in persons having received multiple and frequent tetanus and diphtheria vaccine doses including persons with known hypersensitivity to tetanus (Arthus-type hypersensitivity reaction) or diphtheria vaccines.